Vimarsana
Biggest News Aggregation in the World

Page 5 - Bertram Pitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bertram Pitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bertram Pitt Today - Breaking & Trending Today

New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events Seite 1 - Vimarsana News

New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events Seite 1

02.10.2022 - Data presented at the Heart Failure Society of America annual scientific meetingNew analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart ... Seite 1

Salt Substitute Reduces Stroke, CV Events, and Death - Vimarsana News

Salt Substitute Reduces Stroke, CV Events, and Death

Switching from regular salt to a low-sodium salt substitute has major public health benefits, including a reduction in stroke, cardiovascular events, and death, the new landmark SSaSS shows.

FIDELITY: Finerenone Cuts CV Risk in T2D Across CKD Spectrum - Vimarsana News

FIDELITY: Finerenone Cuts CV Risk in T2D Across CKD Spectrum

Importantly, the study saw few cases of hyperkalemia associated with the drug, suggesting it avoids a major problem associated with spironolactone and eplerenone.

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD - Vimarsana News

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

(UPDATED) The study, when coupled with FIDELIO-DKD, now opens up finerenone to diabetic patients with a wide range of CKD.

Source: tctmd.com
Alphagalileo > Item Display - Vimarsana News

Alphagalileo > Item Display

Finerenone reduces the risk of cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease and type 2 diabetes. That’s the....